Genetics, diagnosis and management of colorectal cancer (Review)

Oncology Reports

Volumn 34, Issue 3, 2015, Pages 1087-1096

  De Rosa, Marina ^a   Pace, Ugo ^b   Rega, Daniela ^b   Costabile, Valeria ^a   Duraturo, Francesca ^a   Izzo, Paola ^a,c   Delrio, Paolo ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Colorectal cancer; Conventional laparoscopic surgery; Early diagnosis; Epithelial to mesenchymal transition; Genetic heterogeneity; Hereditary colorectal cancers; Minimally invasive surgery; Molecular signaling pathways; Personalised care; Robotic surgery

Indexed keywords

BETA CATENIN; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; WNT PROTEIN;

ARTICLE; CANCER GENETICS; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL FEATURE; COLON CANCER; COLORECTAL CANCER; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENETIC TRANSCRIPTION; HEREDITARY COLORECTAL CANCER; HUMAN; LAPAROSCOPIC SURGERY; METASTATIC COLORECTAL CANCER; MINIMALLY INVASIVE SURGERY; MOLECULAR DIAGNOSIS; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; ROBOT ASSISTED SURGERY; COLORECTAL NEOPLASMS; GENETICS;

COLORECTAL NEOPLASMS; HUMANS;

EID: 84937197557     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4108     Document Type: Article

References (138)

1. Pancione M, Remo A and Colantuoni V: Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathol Res Int 2012: 509348, 2012.
2. Ewing I, Hurley JJ, Josephides E and Millar A: The molecular genetics of colorectal cancer. Frontline Gastroenterol 5: 26-30, 2014.
3. Vogelstein B, Fearon ER , Hamilton SR , Kern SE , Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
4. Burt RW: Colon cancer screening. Gastroenterology 119: 837-853, 2000.
5. Jasperson KW, Tuohy TM, Neklason DW and Burt R W: Hereditary and familial colon cancer. Gastroenterology 138: 2044-2058, 2010.
6. Duraturo F, Liccardo R, Cavallo A, De Rosa M, Grosso M and Izzo P: Association of low-risk MSH3 and MSH2 variant alleles with Lynch syndrome: Probability of synergistic effects. Int J Cancer 129: 1643-1650, 2011.
7. Rustgi AK: The genetics of hereditary colon cancer (Review). Genes Dev 21: 2525-2538, 2007.
8. Peifer M: Developmental biology: colon construction. Nature 420: 274-275, 277, 2002.
9. Kosinski C, Li VS, Chan AS, Zhang J, Ho C, Tsui WY, Chan TL , Mifflin RC , Powell DW, Yuen ST , et al: Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA 104: 15418-15423, 2007.
10. Medema JP and Vermeulen L: Microenvironmental regulation of stem cells in intestinal homeostasis and cancer (Review). Nature 474: 318-326, 2011.
11. Goel A, Nagasaka T, Arnold CN , Inoue T, Hamilton C , Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, et al: The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132: 127-138, 2007.
12. Sideris M and Papagrigoriadis S: Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer (Review). Anticancer Res 34: 2061-2068, 2014.
13. Pino MS and Chung DC: The chromosomal instability pathway in colon cancer. Gastroenterology 138: 2059-2072, 2010.
14. Boland CR and Goel A: Microsatellite instability in colorectal cancer (Review). Gastroenterology 138: 2073-2087.e3, 2010.
15. Colussi D, Brandi G, Bazzoli F and Ricciardiello L: Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 14: 16365-16385, 2013.
16. Markowitz SD and Bertagnolli MM: Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361: 2449-2460, 2009.
17. Najdi R, Holcombe RF and Waterman ML: Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog 10: 5, 2011.
18. MacDonald BT , Tamai K and He X: Wnt/β-catenin signaling: components, mechanisms and diseases. Dev Cell 17: 9-26, 2009.
19. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-51, 2000.
20. Giles RH, van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24, 2003.
21. Dejana E: The role of wnt signaling in physiological and pathological angiogenesis. Circ Res 107: 943-952, 2010.
22. Planutis K, Planutiene M and Holcombe RF: A novel signaling pathway regulates colon cancer angiogenesis through Norrin. Sci Rep 4: 5630, 2014.
23. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006.
24. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
25. Testa JR and Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98: 10983-10985, 2001.
26. Martini M, De Santis MC, Braccini L, Gulluni F and Hirsch E : PI3K/AKT signaling pathway and cancer: an updated review. Ann Med 46: 372-383, 2014.
27. Porta C, Paglino C and Mosca A: Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 4: 64, 2014.
28. Lee G, Goretsky T, Managlia E, Dirisina R, Singh AP, Brown JB, May R , Yang GY, Ragheb JW, Evers BM, et al: Phosphoinositide 3-kinase signaling mediates β-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology 139: 869-881, 2010.
29. Simpson L and Parsons R: PTEN: life as a tumor suppressor. Exp Cell Res 264: 29-41, 2001.
30. Salmena L, Carracedo A and Pandolfi PP: Tenets of PTEN tumor suppression. Cell 133: 403-414, 2008.
31. Manfredi M: Hereditary hamartomatous polyposis syndromes: understanding the disease risks as children reach adulthood. Gastroenterol Hepatol (NY) 6: 185-196, 2010.
32. Eng C: PTEN: one gene, many syndromes. Hum Mutat 22: 183-198, 2003.
33. Galatola M, Paparo L, Duraturo F, Turano M, Rossi GB , Izzo P and De Rosa M: Bcatenin and cytokine pathway dysregulation in patients with manifestations of the 'PTEN hamartoma tumor syndrome'. BMC Med Genet 13: 28, 2012.
34. Alimonti A, Carracedo A, Clohessy JG, Trotman LC , Nardella C , Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E , et al: Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 42: 454-458, 2010.
35. Paparo L, Rossi GB , Delrio P, Rega D, Duraturo F, Liccardo R, Debellis M, Izzo P and De Rosa M: Differential expression of PTEN gene correlates with phenotypic heterogeneity in three cases of patients showing clinical manifestations of PTEN hamartoma tumour syndrome. Hered Cancer Clin Pract 11: 8, 2013.
36. Malumbres M and Barbacid M: RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459-465, 2003.
37. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006.
38. Hallberg B, Rayter SI and Downward J: Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J Biol Chem 269: 3913-3916, 1994.
39. Liebmann C: Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal 13: 777-785, 2001.
40. Shao DD, Xue W, Krall EB , Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, et al: KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158: 171-184, 2014.
41. Chen F and Castranova V: Nuclear factor-kappaB, an unappreciated tumor suppressor. Cancer Res 67: 11093-11098, 2007.
42. Perkins ND: NF-κB: tumor promoter or suppressor? Trends Cell Biol 14: 64-69, 2004.
43. Du Q and Geller DA: Cross-regulation between Wnt and NF-κB signaling pathways. For Immunopathol Dis Therap 1: 155-181, 2010.
44. Hoesel B and Schmid JA: The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12: 1-15, 2013.
45. McCubrey JA, Steelman LS , Bertrand FE, Davis N M, Sokolosky M, Abrams SL , Montalto G, D'Assoro AB, Libra M, Nicoletti F, et al: GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5: 2881-2911, 2014.
46. Li H, Huang K, Liu X, Liu J, Lu X, Tao K, Wang G and Wang J: Lithium chloride suppresses colorectal cancer cell survival and proliferation through ROS/GSK-3β/NF-κB signaling pathway. Oxid Med Cell Longev 2014: 241864, 2014.
47. Mishra R: Glycogen synthase kinase 3β: can it be a target for oral cancer. Mol Cancer 9: 144, 2010.
48. Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, Van't Veer L, Tollenaar RA, Jackson DB, Agrawal D, et al: EMT is the dominant program in human colon cancer. BMC Med Genomics 4: 9, 2011.
49. De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13: 97-110, 2013.
50. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J and García De Herreros A: The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2: 84-89, 2000.
51. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83, 2000.
52. Li X, Pei D and Zheng H; Li X1: Transitions between epithelial and mesenchymal states during cell fate conversions. Protein Cell 5: 580-591, 2014.
53. Mani SA, Guo W, Liao MJ, Eaton EN , Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC , Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008.
54. Giannelli G, Villa E and Lahn M: Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma. Cancer Res 74: 1890-1894, 2014.
55. Costabile V, Duraturo F, Delrio P, Rega D, Pace U, Liccardo R, Rossi GB , Genesio R, Nitsch L, Izzo P, et al: Lithium chloride induces mesenchymal to epithelial reverting transition in primary colon cancer cell cultures. Int J Oncol 46: 1913-1923, 2015.
56. Jasperson KW, Tuohy TM, Neklason DW and Burt R W: Hereditary and familial colon cancer. Gastroenterology 138: 2044-2058, 2010.
57. Gallagher DJ, Smith JD, Offit K and Stadler ZK: Diagnosing hereditary colorectal cancer. Clin Colorectal Cancer 9: 205-211, 2010.
58. Lucci-Cordisco E, Risio M, Venesio T and Genuardi M: The growing complexity of the intestinal polyposis syndromes. Am J Med Genet A 161A: 2777-2787, 2013.
59. De Rosa M, Duraturo F, Liccardo R and Izzo P: Hereditary gastrointestinal polyposis: diagnosis, genetic test and risk assessment. Open J Genet 3: 50-58, 2013.
60. Kolfschoten NE , Wouters MW, Gooiker GA, Eddes EH, Kievit J, Tollenaar R A and Marang-van de Mheen PJ: Dutch surgical colorectal audit group: nonelective colon cancer resections in elderly patients: results from the dutch surgical colorectal audit. Dig Surg 29: 412-419, 2012.
61. Smothers L, Hynan L, Fleming J, Turnage R, Simmang C and Anthony T : Emergency surgery for colon carcinoma. Dis Colon Rectum 46: 24-30, 2003.
62. Kekelidze M, D'Errico L, Pansini M, Tyndall A and Hohmann J: Colorectal cancer: current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. World J Gastroenterol 19: 8502-8514, 2013.
63. Leufkens AM, van den Bosch MA, van Leeuwen MS and Siersema PD: Diagnostic accuracy of computed tomography for colon cancer staging: a systematic review. Scand J Gastroenterol 46: 887-894, 2011.
64. Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J and Bouvier AM: Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 59: 1383-1388, 2010.
65. Barret M, Boustiere C, Canard JM, Arpurt JP, Bernardini D, Bulois P, Chaussade S, Heresbach D, Joly I, Lapuelle J, et al: Société Fransaise d'Endoscopie Digestive: factors associated with adenoma detection rate and diagnosis of polyps and colorectal cancer during colonoscopy in France: results of a prospective, nationwide survey. PLoS One 8: e68947, 2013.
66. Kaminski MF, Regula J, Kraszewska E, Polkowski M, Wojciechowska U, Didkowska J, Zwierko M, Rupinski M, Nowacki MP and Butruk E: Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 362: 1795-1803, 2010.
67. Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I , van B allegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, et al: Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366: 687-696, 2012.
68. Graser A, Stieber P, Nagel D, Schäfer C, Horst D, Becker CR , Nikolaou K, Lottes A, Geisbüsch S, Kramer H, et al: Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 58: 241-248, 2009.
69. Pickhardt PJ, Hassan C, Halligan S and Marmo R: Colorectal cancer: CT colonography and colonoscopy for detection - systematic review and meta-analysis. Radiology 259: 393-405, 2011.
70. Pullens HJ, van Leeuwen MS, Laheij RJ, Vleggaar FP and Siersema PD: CT-colonography after incomplete colonoscopy: What is the diagnostic yield? Dis Colon Rectum 56: 593-599, 2013.
71. Atkin W, Dadswell E, Wooldrage K, Kralj-Hans I, von Wagner C , Edwards R , Yao G, Kay C, Burling D, Faiz O, et al: SIGG AR investigators: computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGG AR): a multicentre randomised trial. Lancet 381: 1194-1202, 2013.
72. Edge SB and Compton CC : The American Joint Committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TN M. Ann Surg Oncol 17: 1471-1474, 2010.
73. Bipat S, Niekel MC, Comans EF, Nio CY, Bemelman WA, Verhoef C and Stoker J: Imaging modalities for the staging of patients with colorectal cancer. Neth J Med 70: 26-34, 2012.
74. Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L and Giovagnoni A: Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 31: 19-31, 2010.
75. Niekel MC, Bipat S and Stoker J: Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 257: 674-684, 2010.
76. Dighe S, Blake H, Koh MD, Swift I, Arnaout A, Temple L , Barbachano Y and Brown G: Accuracy of multidetector computed tomography in identifying poor prognostic factors in colonic cancer. Br J Surg 97: 1407-1415, 2010.
77. Dighe S, Purkayastha S, Swift I, Tekkis PP, Darzi A, A'Hern R and Brown G : Diagnostic precision of CT in local staging of colon cancers: A meta-analysis. Clin Radiol 65: 708-719, 2010.
78. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B , Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, et al: ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23: 2479-2516, 2012.
79. Glimelius B, Beets-Tan R, Blomqvist L, Brown G, Nagtegaal I , Phlman L, Quirke P, Valentini V and van de Velde C: Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J Clin Oncol 29: 2142-2143, 2011.
80. van de Velde CJ, Aristei C, Boelens PG, Beets-Tan RG , Blomqvist L , Borras JM, van den Broek CB , Brown G, Coebergh JW, Cutsem EV, et al: European registration of cancer care: EURECC A colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. Eur J Cancer 49: 2784-2790, 2013.
81. Torkzad MR, Phlman L and Glimelius B: Magnetic resonance imaging (MRI) in rectal cancer: a comprehensive review. Insights Imaging 1: 245-267, 2010.
82. Poston GJ, Tait D, O'Connell S, Bennett A and Berendse S : Guideline development group: diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ 343: d6751, 2011.
83. Swartling T, Kälebo P, Derwinger K, Gustavsson B and Kurlberg G: Stage and size using magnetic resonance imaging and endosonography in neoadjuvantly-treated rectal cancer. World J Gastroenterol 19: 3263-3271, 2013.
84. Hohenberger W, Weber K, Matzel K, Papadopoulos T and Merkel S: Standardized surgery for colonic cancer: complete mesocolic excision and central ligation - technical notes and outcome. Colorectal Dis 11: 354-364, discussion 364-365, 2009.
85. Sehgal R and Coffey JC: Historical development of mesenteric anatomy provides a universally applicable anatomic paradigm for complete/total mesocolic excision. Gastroenterol Rep (Oxf) 2: 245-250, 2014.
86. Søndenaa K, Quirke P, Hohenberger W, Sugihara K, Kobayashi H, Kessler H, Brown G, Tudyka V, D'Hoore A, Kennedy R H, et al: The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery: proceedings of a consensus conference. Int J Colorectal Dis 29: 419-428, 2014.
87. Siani LM and Pulica C: Stage I-IIIC right colonic cancer treated with complete mesocolic excision and central vascular ligation: quality of surgical specimen and long term oncologic outcome according to the plane of surgery. Minerva Chir 69: 199-208, 2014.
88. Sagar J: Colorectal stents for the management of malignant colonic obstructions. Cochrane Database Syst Rev 11: CD007378, 2011. Review.
89. Fuccio L, Cennamo V and de Bellis M: Risk factors for stent-related adverse events in patients with obstructive colorectal cancer: are we missing something? Gastrointest Endosc 80: 742-743, 2014.
90. Fuccio L, Correale L, Arezzo A, Repici A, Manes G, Trovato C , Mangiavillano B , Manno M, Cortelezzi CC , Dinelli M, et al; KRASTENT Study Group: influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: a retrospective multicentre study. Dig Liver Dis 46: 561-567, 2014.
91. Yang TX and Chua TC: Single-incision laparoscopic colectomy versus conventional multiport laparoscopic colectomy: a meta-analysis of comparative studies. Int J Colorectal Dis 28: 89-101, 2013.
92. Mynster T, Hammer J and Wille-Jørgensen P: Preliminary results after single-port laparoscopic colonic surgery. Dan Med J 59: A4551, 2012.
93. Huscher CG , Mingoli A, Sgarzini G, Mereu A, Binda B , Brachini G and Trombetta S: Standard laparoscopic versus single-incision laparoscopic colectomy for cancer: early results of a randomized prospective study. Am J Surg 204: 115-120, 2012.
94. Wolthuis AM, Penninckx F, Fieuws S and D'Hoore A: Outcomes for case-matched single-port colectomy are comparable with conventional laparoscopic colectomy. Colorectal Dis 14: 634-641, 2012.
95. Ramos-Valadez DI, Ragupathi M, Nieto J, Patel CB , Miller S , Pickron TB and Haas EM: Single-incision versus conventional laparoscopic sigmoid colectomy: a case-matched series. Surg Endosc 26: 96-102, 2012.
96. Tyler JA, Fox JP, Desai MM, Perry WB and Glasgow SC : Outcomes and costs associated with robotic colectomy in the minimally invasive era. Dis Colon Rectum 56: 458-466, 2013.
97. Baek SK, Carmichael JC and Pigazzi A: Robotic surgery: colon and rectum. Cancer J 19: 140-146, 2013.
98. Glimelius B, Beets-Tan R, Blomqvist L, Brown G, Nagtegaal I , Phlman L, Quirke P, Valentini V and van de Velde C: Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J Clin Oncol 29: 2142-2143, 2011.
99. Sgourakis G, Lanitis S, Gockel I, Kontovounisios C, Karaliotas C, Tsiftsi K, Tsiamis A and Karaliotas CC : Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes. Am Surg 77: 761-772, 2011.
100. Guerrieri M, Gesuita R, Ghiselli R, Lezoche G, Budassi A and Baldarelli M: Treatment of rectal cancer by transanal endoscopic microsurgery: experience with 425 patients. World J Gastroenterol 20: 9556-9563, 2014.
101. Matz J a nd Matz A: Use of a SILS p ort i n t ransanal endoscopic microsurgery in the setting of a community hospital. J Laparoendosc Adv Surg Tech A 22: 93-96, 2012.
102. Atallah S, Albert M and Larach S: Transanal minimally invasive surgery: a giant leap forward. Surg Endosc 24: 2200-2205, 2010.
103. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, Heath R M and Brown JM: MRC CL ASICC trial group: short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CL ASICC trial): multicentre, randomised controlled trial. Lancet 365: 1718-1726, 2005.
104. Jayne DG, Thorpe HC, Copeland J, Quirke P, Brown JM and Guillou PJ: Five-year follow-up of the Medical Research Council CL ASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg 97: 1638-1645, 2010.
105. Kang SB , Park JW, Jeong SY, Nam BH, Choi HS, Kim DW, Lim SB , Lee TG , Kim DY, Kim JS, et al: Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (CORE AN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol 11: 637-645, 2010.
106. van der Pas MH, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC and Bonjer HJ: Colorectal cancer laparoscopic or open resection II (COLOR II) study group: laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol 14: 210-218, 2013.
107. Yang Y, Wang F, Zhang P, Shi C, Zou Y, Qin H and Ma Y: Robot-assisted versus conventional laparoscopic surgery for colorectal disease, focusing on rectal cancer: a meta-analysis. Ann Surg Oncol 19: 3727-3736, 2012.
108. Lin S, Jiang HG, Chen ZH, Zhou SY, Liu XS and Yu JR: Meta-analysis of robotic and laparoscopic surgery for treatment of rectal cancer. World J Gastroenterol 17: 5214-5220, 2011.
109. Park JS, Choi GS, Lim KH, Jang YS and Jun SH: S052: a comparison of robot-assisted, laparoscopic, and open surgery in the treatment of rectal cancer. Surg Endosc 25: 240-248, 2011.
110. Kim JC, Yang SS , Jang TY, Kwak JY, Yun MJ and Lim SB : Open versus robot-assisted sphincter-saving operations in rectal cancer patients: techniques and comparison of outcomes between groups of 100 matched patients. Int J Med Robot 8: 468-475, 2012.
111. Kim JY, Kim N-K, Lee KY, Hur H, Min BS and Kim JH: A comparative study of voiding and sexual function after total mesorectal excision with autonomic nerve preservation for rectal cancer: laparoscopic versus robotic surgery. Ann Surg Oncol 19: 2485-2493, 2012.
112. D'Annibale A, Pernazza G, Monsellato I, Pende V, Lucandri G , Mazzocchi P and Alfano G: Total mesorectal excision: a comparison of oncological and functional outcomes between robotic and laparoscopic surgery for rectal cancer. Surg Endosc 27: 1887-1895, 2013.
113. Luca F, Valvo M, Ghezzi TL , Zuccaro M, Cenciarelli S, Trovato C , Sonzogni A and Biffi R: Impact of robotic surgery on sexual and urinary functions after fully robotic nerve-sparing total mesorectal excision for rectal cancer. Ann Surg 257: 672-678, 2013.
114. Collinson FJ, Jayne DG, Pigazzi A, Tsang C, Barrie JM, Edlin R, Garbett C, Guillou P, Holloway I, Howard H, et al: An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. Int J Colorectal Dis 27: 233-241, 2012.
115. Memon S, Heriot AG, Murphy DG, Bressel M and Lynch AC: Robotic versus laparoscopic proctectomy for rectal cancer: a meta-analysis. Ann Surg Oncol 19: 2095-2101, 2012.
116. Trastulli S, Farinella E, Cirocchi R, Cavaliere D, Avenia N , Sciannameo F, Gullà N, Noya G and Boselli C: Robotic resection compared with laparoscopic rectal resection for cancer: systematic review and meta-analysis of short-term outcome. Colorectal Dis 14: e134-e156, 2012.
117. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R , Borras JM, Haustermans K, Maingon P, Overgaard J, Pahlman L , et al: Scientific committee: multidisciplinary rectal cancer management: 2nd European rectal cancer consensus conference (EUREC A-CC 2). Radiother Oncol 92: 148-163, 2009.
118. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C , Becker H, Raab HR, Villanueva MT, Witzigmann H, et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO /AIO -94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30: 1926-1933, 2012.
119. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B , Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, et al: ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23: 2479-2516, 2012.
120. Pettersson D, Glimelius B, Iversen H, Johansson H, Holm T and Martling A: Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br J Surg 100: 969-975, 2013.
121. Pettersson D, Cedermark B, Holm T, Radu C, Phlman L , Glimelius B and Martling A: Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 97: 580-587, 2010.
122. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M and Kryj M: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93: 1215-1223, 2006.
123. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan S A, et al: Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-tasman radiation oncology group trial 01.04. J Clin Oncol 30: 3827-3833, 2012.
124. Siegel R, Burock S, Wernecke KD, Kretzschmar A, Dietel M, Loy V, Koswig S, Budach V and Schlag PM: Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer 9: 50, 2009.
125. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S , Hartmann JT, Müller L, Link H, Moehler M, Kettner E, et al: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13: 579-588, 2012.
126. Avallone A, Delrio P, Pecori B, Tatangelo F, Petrillo A, Scott N , Marone P, Aloi L, Sandomenico C, Lastoria S, et al: Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome. Int J Radiat Oncol Biol Phys 79: 670-676, 2011.
127. Gunderson LL, Jessup JM, Sargent DJ, Greene FL and Stewart AK: Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 28: 264-271, 2010.
128. Bombard Y, Bach PB and Offit K: Translating genomics in cancer care. J Natl Compr Canc Netw 11: 1343-1353, 2013.
129. Ross JS and Cronin M: Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol 136: 527-539, 2011.
130. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN , French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257, 2003.
131. Bertagnolli MM, Niedzwiecki D, Compton CC , Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg R M, Saltz LB , et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. J Clin Oncol 27: 1814-1821, 2009.
132. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF and B : Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 45: 1890-1896, 2009.
133. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR , French AJ, Kabat B, Foster NR , Torri V, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28: 3219-3226, 2010.
134. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22, 2003.
135. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, et al: Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLO X) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 30: 1755-1762, 2012.
136. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706-4713, 2010.
137. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR , Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009.
138. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N , Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S , et al: Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13: 1438-1446, 2002.